A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma - Trial NCT04444141
Access comprehensive clinical trial information for NCT04444141 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Akeso and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Akeso
Timeline & Enrollment
Phase 1/2
May 15, 2020
Jun 30, 2022
Primary Outcome
Objective response rate (ORR)
Summary
The purpose of this study is to evaluate the efficacy and safety of AK104๏ผan anti- PD-1 and
 CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell
 lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed
 disease progression, withdrawal of consent, or for a maximum of 24 months.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04444141
Non-Device Trial